Health
Wegovy Maker Sues US Pharmacy to Block Knock-Off
- Compounding pharmacies make, sell Wegovy’s active ingredient
- Manufacturer alleges pharmacies sell unapproved drugs
This article is for subscribers only.
Novo Nordisk A/S sued US pharmacies making and selling versions of semaglutide, the active ingredient in Wegovy, the company’s blockbuster weight-loss drug.
In lawsuits filed Thursday in Florida and Tennessee federal courts, Novo said that the compounding pharmacies violate state law by selling drugs that lack Food and Drug Administration approval and haven’t been sufficiently studied.